Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
16 10월 2023 - 9:11PM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
positive data from a preclinical study investigating
the binding affinity and optimization of SPU-21 liposomal
joint homing peptide in human synovial tissue surrounding joints
and tendons. SPU-21 selectively targets inflamed synovial tissue to
inhibit the progression of rheumatoid arthritis (RA).
“The purpose of this study was to expand our investigation of
our patented SPU-21 cyclic peptide beyond preclinical animal models
to human tissue assays,” said Eric Weisblum, Chief Executive
Officer of Silo Pharma. “The data shows strong binding affinity to
the main stromal cells in human RA synovial tissue, indicating the
peptides’ preferential interaction with the inflamed synovial
tissue for disease-suppressive effects. We look forward to our next
data readout for SPU-21 by the end of the year or early
2024.”
The University of Maryland, Baltimore (UMB) is Silo Pharma’s
collaboration partner for SPU-21 development. In addition to
SPU-21, Silo Pharma holds a license agreement with UMB for a
central nervous system (CNS) homing peptide targeting multiple
sclerosis (MS) and other rare neurological diseases designated.
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical
company focused on merging traditional therapeutics with
psychedelic research for people suffering from indications such as
PTSD, Alzheimer’s disease, and other rare neurological disorders.
Silo’s mission is to identify assets to license and fund the
research which we believe will be transformative to the well-being
of patients and the healthcare industry. For more information visit
www.silopharma.com
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements that involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company undertakes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's filings with the SEC.
Contact
800-705-0120 investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Silo Pharma (NASDAQ:SILO)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024